Fundamental, Research

Consumer Staples: Risks From Anti-Obesity Medications Likely Overblown

Arun Sundaram, CFA, CPA, VP of Equity Research
18 December 2023


Anti-obesity medications (AOMs), including glucagon-like peptide-1 (GLP-1) agonists, have recently seen a substantial increase in popularity. Initially developed for type 2 diabetes management due to their ability to regulate blood sugar levels, these medications have found a new application in weight management. They work by slowing down the movement of food through the stomach, which helps individuals feel fuller sooner and for a longer duration.

Want to learn more? Download the Report.


Fundamental Equity Research
Gain a comprehensive view of global themes, industries, and companies.

Related Insights

Amazon: $7+ EPS by 2025 Could Be the Next Catalyst

Amazon: $7+ EPS by 2025 Could Be the Next Catalyst

Wall Street has historically valued AMZN shares using nontraditional relative valuation metrics.
Read more